Low-value approvals and high prices might incentivize ineffective drug development

Low-value approvals and high prices might incentivize ineffective drug developmentLow-value approvals and high prices might incentivize ineffective drug development, Published online: 14 May 2018; doi:10.1038/s41571-018-0030-2Drug regulators’ acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research